BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16879770)

  • 1. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
    Duvic M; Talpur R; Wen S; Kurzrock R; David CL; Apisarnthanarax N
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):51-8. PubMed ID: 16879770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
    Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
    Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gemcitabine Monotherapy for Advanced Mycosis Fungoides--Two Case Reports and a Literature Review].
    Masuzawa M; Takasu H; Amoh Y
    Gan To Kagaku Ryoho; 2015 Dec; 42(13):2451-5. PubMed ID: 26809303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases.
    Jidar K; Ingen-Housz-Oro S; Beylot-Barry M; Paul C; Chaoui D; Sigal-Grinberg M; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2009 Sep; 161(3):660-3. PubMed ID: 19438862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
    Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
    Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network.
    Blazejak C; Stranzenbach R; Gosman J; Gambichler T; Wehkamp U; Stendel S; Klemke CD; Wobser M; Olk J; Nicolay JP; Weyermann M; Stadler R; Assaf C
    Dermatology; 2022; 238(3):498-506. PubMed ID: 34474414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
    Marchi E; Alinari L; Tani M; Stefoni V; Pimpinelli N; Berti E; Pagano L; Bernengo MG; Zaja F; Rupoli S; Pileri S; Baccarani M; Zinzani PL
    Cancer; 2005 Dec; 104(11):2437-41. PubMed ID: 16216001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
    Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
    Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
    Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acitretin for the treatment of cutaneous T-cell lymphoma.
    Cheeley J; Sahn RE; DeLong LK; Parker SR
    J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
    Illidge T; Chan C; Counsell N; Morris S; Scarisbrick J; Gilson D; Popova B; Patrick P; Smith P; Whittaker S; Cowan R
    Br J Cancer; 2013 Nov; 109(10):2566-73. PubMed ID: 24136145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
    Zinzani PL; Baliva G; Magagnoli M; Bendandi M; Modugno G; Gherlinzoni F; Orcioni GF; Ascani S; Simoni R; Pileri SA; Tura S
    J Clin Oncol; 2000 Jul; 18(13):2603-6. PubMed ID: 10893292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.
    Di Raimondo C; Vaccarini S; Nunzi A; Rapisarda V; Zizzari A; Meconi F; Monopoli A; Narducci MG; Scala E; Bianchi L; Tesei C; Cantonetti M
    Dermatol Ther; 2022 Jun; 35(6):e15482. PubMed ID: 35373414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alitretinoin in the treatment of cutaneous T-cell lymphoma.
    Kaemmerer T; Stadler PC; Helene Frommherz L; Guertler A; Einar French L; Reinholz M
    Cancer Med; 2021 Oct; 10(20):7071-7078. PubMed ID: 34435474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
    Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
    Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
    Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
    Actas Dermosifiliogr; 2024 Jun; 115(6):T547-T554. PubMed ID: 38653368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
    Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
    Actas Dermosifiliogr; 2024 Jun; 115(6):547-554. PubMed ID: 38395224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.